BioGaia AB (publ) (BIOG_B) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to BIOGaia Q1 Report for 2026. Now I will hand the conference over to CEO, Teresa Agnew and CFO, Alexander Kotzinez. Please go ahead. Hi, this is Teresa Agnew, CEO of BIOGaia, and we are here to present our Q1 twenty twenty six results. So in terms of the highlights, we have growth, excluding currency effects, of 15%. Our EBIT margin for the quarter is 27%. And overall, our free cash flow is SEK67 million. Our net sales reached SEK373 million, And as I said, growth of 15%, 2% growth when you include currency effects. By region, our Asia Pacific region increased by 6% excluding currency effects. In The Americas, we increased by 12% excluding currency effects. And for Europe, Middle East, Africa, we increased by 24% excluding currency effects. Our operating profit for the quarter was around million, which is 4% growth. And our EBIT margin, as I said, was 27% comparing to 27% same quarter last year. To remind you of our company's strategy, we have three strategic pillars. Grow the core, where we focus on growing our core health areas. Gut health, of which colic is a part, oral health, and immune health. Our second strategic pillar is what we call expansion through direct markets. So focusing on growing our current 12 direct markets, and focusing our marketing and selling and investment activities in those markets to drive growth ahead of market. And our third strategic pillar is what we call breakthrough innovation, where we work on new products that are in new areas as a new market creation opportunities for probiotics. And our foundations are, of course, our people and our culture investing for profitable growth, using digital as an enabler of the business, both in how we go to market in our omnichannel approach, as well as how we digitize internally to make u...